Lemsip Multirelief capsules
*Company:
Reckitt Benckiser Ireland LimitedStatus:
UpdatedLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 13 December 2024
File name
Lemsip Multi Relief PIL (clean) Nov24.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - dose and frequency
- Change to section 4 - possible side effects
Updated on 13 December 2024
File name
Lemsip Multi Relief SmPC (clean) Nov24.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
Legal category:Supply through pharmacy only
Updated on 04 August 2022
File name
SPC Nat Phase Lemsip Multi Relief Caps zippy Dec21 CRN00CJS9.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through pharmacy only
Updated on 04 August 2022
File name
PIL Lemsip Multi Relief TR2329024-D CRN008LCT & CRN008TSD & CRN00C22J & CRN00CJS9 & CRN00CQMZ Dec21.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 27 October 2021
File name
IE SPC cleean Aug21.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through pharmacy only
Updated on 15 January 2020
File name
Lemsip Multi Relief Capsules.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 28 February 2018
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 28 February 2018
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Approval of Renewal date added to Section 9 (Renewal approval received Jan 2018)
Updated on 02 March 2017
File name
PIL_14939_142.pdf
Reasons for updating
- New PIL for new product
Updated on 02 March 2017
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - how to take/use
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store or dispose
Updated on 01 December 2016
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.5:
Additional information for paracetamol & phenylephrine HCl interactions
Section 4.6:
Additional safety data on phenylephrine HCl
Section 4.7:
Addition of "No or negligible influence on ability to drive or use machinery"
Section 4.8:
Addition of blood dyscrasias symptoms
Addition of hypersensitivity reactions as an adverse reaction for Guaifenesin.
Section 4.9:
Addition o f overdose data for paracetamol and phenylephrine HCl
Additional information for paracetamol & phenylephrine HCl interactions
Section 4.6:
Additional safety data on phenylephrine HCl
Section 4.7:
Addition of "No or negligible influence on ability to drive or use machinery"
Section 4.8:
Addition of blood dyscrasias symptoms
Addition of hypersensitivity reactions as an adverse reaction for Guaifenesin.
Section 4.9:
Addition o f overdose data for paracetamol and phenylephrine HCl
Updated on 03 December 2012
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 6.3, the shelf-life has changed from 2-3 years
In section 10, the date of revision of the text has changed to November 2012
In section 10, the date of revision of the text has changed to November 2012
Updated on 30 March 2011
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
None provided
Updated on 29 March 2011
Reasons for updating
- New PIL for new product